TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00999687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indigo Naturalis Extract in Oil
Description: Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Indigo Naturalis Extract in Oil
Description: Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: Olive oil was applied to the fingernails of the contra-lateral hand (control group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
Study: NCT01126606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacid Silver (Lactic acid)
Description: Liquid soap, daily use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermacid Silver (Lactic acid)
Description: Liquid soap, daily use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerine Vegetal Soap Granado Traditional
Description: Vegetal soap, daily use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycerine Vegetal Soap Granado Traditional
Description: Vegetal soap, daily use
Study: NCT01717040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
Study: NCT03673592

Intervention type: DIAGNOSTIC_TEST
Intervention: PGT-A
Description: PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.

Intervention type: DIAGNOSTIC_TEST
Intervention: PGT-A
Description: PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.

Intervention type: DIAGNOSTIC_TEST
Intervention: PGT-A
Description: PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.

Intervention type: DIAGNOSTIC_TEST
Intervention: PGT-A
Description: PGT-A will be carried out following the usual clinical practice: Trophectoderm biopsy samples from blastocysts are analyzed by NGS to screen for numerical chromosomal abnormalities.
Study: NCT02007447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OCYTOCINA - SPRAY NASAL
Description: The initial sample is divided into two groups (A and B): group A receive oxytocin intranasal for 8 weeks 24UI twice a day (3 applications per nostril 4UI 12/12 hours); group B will receive placebo for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OCYTOCINA - SPRAY NASAL
Description: The initial sample is divided into two groups (A and B): group A receive oxytocin intranasal for 8 weeks 24UI twice a day (3 applications per nostril 4UI 12/12 hours); group B will receive placebo for 8 weeks
Study: NCT03746444

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: The patients in general anesthesia group will undergo general anesthesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia
Description: The patients in Group R will be given combined spinoepidural anesthesia
Study: NCT01899209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: STARR

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Ventral Rectopexy
Study: NCT01253915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Carbon Dioxide
Description: 10 sec/nostril up to 4 times to treat one migraine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 sec/nostril up to 4 times to treat a migraine
Study: NCT01101906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: OSI-906 administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally
Study: NCT02057380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linsitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linsitinib
Description: oral
Study: NCT01489787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIFU
Description: The shootings will concern healthy liver to be resected, distant (step 1) then close (step 2) to the important vascular structures of the liver. Several shootings HIFU will be made on each patient (ideally 4 hurts, minimum 2 hurts)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIFU
Description: Shootings will concern small metastases (≤ 20 mm) and peri lesional healthy liver. They will be juxtaposed on multiple plans in order to generate a large hurt containing the metastasis targeted and guaranteeing a sufficient safety margin in healthy liver.~Several metastases can be treated in the same patient
Study: NCT04370028

Intervention type: DRUG
Intervention: Divaza
Description: Oral administration.
Study: NCT02776280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal
Description: Typical Brazilian meal consisting of rice, beans and meat with vegetables

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal
Description: Typical Brazilian meal consisting of rice, beans and meat with vegetables
Study: NCT02057380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linsitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linsitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linsitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linsitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linsitinib
Description: oral
Study: NCT02776280

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Meal
Description: Typical Brazilian meal consisting of rice, beans and meat with vegetables
Study: NCT02057380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linsitinib
Description: oral
Study: NCT01108809

Intervention type: DRUG
Intervention: Telmisartan or Telmisartan and Hydrochlorthiazide
Description: Telmisartan 80mg +/- Hydrochlorthiazide 12.5mg or 25mg
Study: NCT02057380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linsitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linsitinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous (IV) infusion
Study: NCT00400491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (vitamin D)
Description: Cholecalciferol capsule 20.000 IU twice per week for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule twice a week, identical to the cholecalciferol capsules
Study: NCT03334578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastrografin
Description: Gastrografin group
Study: NCT03435653

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OFD with DFDBA
Description: Control Group Open flap debridement with DFDBA Periodontal surgery will be performed in the form of open flap debridement along with placement of demineralized freeze dried bone allograft at the defect site.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OFD with decortication and DFDBA
Description: Test Group Open flap debridement with decortication and demineralised freeze dried bone allograft Open flap debridement with decortication and placement of demineralized freeze dried bone allograft at the defect site.
Study: NCT03175380

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bacillus Calmette-Guérin
Description: BCG injection for prevention of tuberculosis
Study: NCT03319992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upper Arm Rehabilitation Light Exoskeleton (RH-LEXOS)
Description: RH-LEXOS is a robotic exoskeleton device to support the rehabilitation of stroke patients. This system is conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. Passive, assisted and active mobilization of upper arm is provided through the use of the exoskeleton robotic device within high intensive, repetitive, task-oriented exercises and an objective and reliable mean for monitoring patients' progress.
Study: NCT01764646

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Description: Minimize radiation doses to surrounding area

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy
Description: Minimize radiation doses to surrounding area

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Volumetric modulated arc therapy
Description: Highly conformational dose distribution

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Volumetric modulated arc therapy
Description: Highly conformational dose distribution

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image guided radiation therapy
Description: Follow target by the use of fiducial markers and ERB

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image guided radiation therapy
Description: Follow target by the use of fiducial markers and ERB
Study: NCT00002706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Surgery
Description: Undergo vaginal hysterectomy and BSO via laparoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: Undergo total abdominal hysterectomy and BSO via conventional laparotomy
Study: NCT02892851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation of the subthalamic nuclei (STN-DBS)
Description: 3 phases :~* Parameter setting~* Cross-over double-bind (ON/OFF)~* Open Phase (ON)
Study: NCT01269645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Trial educational materials
Description: Usual care and (1) a 10-minute clinical trials educational video; and (2) a 12-page educational booklet to accompany the educational video. Content includes basic information about clinical trials and patient testimonials about the value and benefits of participating in clinical trials. The video also addresses common misperceptions about clinical trials using patient and physician testimonials. After watching the video, participants will be provided a copy of the video for home viewing, along with the educational booklet to be reviewed at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Trial educational materials
Description: Usual care and (1) a 10-minute clinical trials educational video; and (2) a 12-page educational booklet to accompany the educational video. Content includes basic information about clinical trials and patient testimonials about the value and benefits of participating in clinical trials. The video also addresses common misperceptions about clinical trials using patient and physician testimonials. After watching the video, participants will be provided a copy of the video for home viewing, along with the educational booklet to be reviewed at home.
Study: NCT00834353

Intervention type: DRUG
Intervention: ATT
Study: NCT04194333

Intervention type: PROCEDURE
Intervention: Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy to guide Electromagnetic Navigational Bronchoscopy instead of Standard Fluroscopic guidance using the C-Arm
Description: Instead of the standard fluoroscopy using the C-arm, the intervention will undergo electromagnetic navigation guided bronchoscopy while using Cone Beam CT with Embo Guide to creat 3D Overlay and CT Augmented Fluoroscopy.
Study: NCT00882245

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ointment
Description: Topical vehicle cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ointment
Description: SRD441 Ointment
Study: NCT00659828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant methionyl human leptin
Description: Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
Study: NCT01165060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Description: Week 0 to 12: 400 mg once daily 1 tablet. Week 13 to 24: 400 mg once daily 2 tablets.
Study: NCT02686567

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: with TDT
Description: After completion of the anastomosis and further DS construction if necessary, the surgeon would be notified to implement the intervention based on the randomizing results. In this group, a silicone tube (28Fr, Sumitomo Bakelite Co, Japan) was inserted through the anus and the tip of the tube was placed approximately 5 cm above the anastomosis at the end of the surgery in patients from the TDT group. The tube was fixed with a skin suture and connected to a drainage bag. TDT was planed to remove 3-7 days after surgery and early removal was allowed if the patient experienced intolerable pain.
Study: NCT04410770

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mood tracker ratings
Description: The participant rates his/her emotional distress several times a week using a specially developed smart phone app. The participant receives support call to ensure that self-ratings are being completed.
Study: NCT01486485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heparinized saline priming group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nafamostat infusion after heparinized saline priming
Study: NCT05550610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Attention Training (MBAT) and Yoga
Description: Mindfulness-Based Attention Training (MBAT) was delivered in 4, 2-hour sessions over 4 weeks. Participants also completed 15 minutes of group mindfulness practice 6 days/week and received information on embedded practice during the duty day. Yoga was delivered 6 days/week, 30 minutes per day during warm-up (15 min) and cool-down (15 min) as part of Army physical readiness training.
Study: NCT01759485

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: once weekly oral drops preparation at a daily dose of 2000 IU X 7 = 14,000 IU per week (about 60 drops each week).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01642667

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prourokinase
Description: a bolus of 1.2 million IU and an infusion of 4.8 million IU in 60 min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02965456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP 121 Lotion
Description: IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-121 Vehicle Lotion
Description: IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
Study: NCT04562519

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: Patients of this group will receive 20 minutes of extra oral TENS over skin of bilateral parotid glands (3 sessions weekly for 3 weeks)
Study: NCT03555773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipogems
Description: After local surgical drainage of the perianal disease, micro-fragmented adipose tissue is injected circumferentially into the submucosa surrounding the internal fistula orifice and in the perianal tissue along the residual fistula tract.
Study: NCT00792831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357
Description: Histone-Deacetylase Inhibitor
Study: NCT02096939

Intervention type: PROCEDURE
Intervention: Adrenal extirpation

Intervention type: DRUG
Intervention: Antihypertensive medication
Study: NCT02898116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: Ensartinib was administered orally once daily at a dose of 200 mg during the Run-in Period. During combination therapy, the ensartinib starting dose was to be 200 mg. Based on observed toxicity at the starting dose level, the ensartinib dose may have been escalated to the recommended single-agent dose (225 mg) or de-escalated to the minimum effective dose (150 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: During combination therapy, durvalumab was to be administered as an IV infusion over 60 (± 5) minutes every 4 weeks at a dose of 1500 mg.
Study: NCT01384279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin, topiramate
Description: metformin 250 mg/d is gradually increased to 1000 mg/d over four weeks, and topiramate 50 mg/d is gradually increased to 200 mg/d over four weeks
Study: NCT01846520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive FCPCI home education sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based intervention
Description: Receive FCPCI telephone support sessions and 24 hour telephone support

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT04424524

Intervention type: OTHER
Group type: OTHER
Intervention: Direct-to-pharmacy oral PrEP refill visits
Description: Programmatic direct-to-pharmacy oral PrEP refill visits supported with client HIV self-testing
Study: NCT01232205

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: micronutrient antioxidant
Description: Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: supplementation with milk
Study: NCT00744471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: Tanezumab 10 mg IV every 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: Tanezumab 5mg IV every 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tanezumab
Description: Tanezumab 2.5 mg IV every 8 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match tanezumab IV every 8 weeks
Study: NCT00644748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Description: Gabapentin oral capsules:~Week 0: Day 1: 300 mg; Day 2: 600 mg (2 doses of 300 mg); Day 3: 900 mg (3 doses of 300 mg), maintained until the end of the week; After this point, the total daily dose was divided in 3 equal doses. Week 1: Day 1: 1200 mg; Day 2 to 7: 1800 mg Week 2: Day 1: 2100 mg; Day 2 to 7: 2400 mg Week 3: Day 1: 2700 mg; Day 2 to 7: 3600 mg Weeks 4 to 11: 3600 mg
Study: NCT04478331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-based physical activity interventions
Description: The technology groups will receive a PA program for 12 weeks. These PA programs will be given twice a week and include: 5-10 minutes of warm-up, 20-40 minutes of aerobic exercise and muscle strengthening via circuit training composed of 8-10 exercises with 8-12 repetitions per exercise for 2-3 series, and 5-10 minutes of stretching. In addition, advice and counseling will be given about walking activities to achieve the recommendations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-based physical activity interventions
Description: The technology groups will receive a PA program for 12 weeks. These PA programs will be given twice a week and include: 5-10 minutes of warm-up, 20-40 minutes of aerobic exercise and muscle strengthening via circuit training composed of 8-10 exercises with 8-12 repetitions per exercise for 2-3 series, and 5-10 minutes of stretching. In addition, advice and counseling will be given about walking activities to achieve the recommendations.
Study: NCT00775385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chemotherapy
Description: Pemetrexed Cisplatin Schedule : CDDP 75 mg/m² D1, pemetrexed 500 mg/m² D1 D1=D21, 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Customized Treatment
Description: Mutated EGFR : Erlotinib 150mg/day (1 year)~Wild-type EGFR or undetermined depends on ERCC1 status :~* ERCC1 high : no treatment~* ERCC1 low or undetermined : Pemetrexed Cisplatin, 4 cycles (63 days)
Study: NCT01488968

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Radiation Treatment
Description: 39 radiation treatments

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation treatment
Description: 25 radiation treatments